AOD-9604 Research: Human Trials, Negative Findings and Limits
Published
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
AOD-9604 was investigated in human obesity trials, and its larger study did not establish a weight-loss advantage over placebo at the primary endpoint. That negative result belongs at the center of an evidence guide. The research record also includes safety reports and later studies under the name LAT8881, so saying the compound was “never tested in people” would be inaccurate.
At a glance:
AOD-9604 is a modified growth-hormone fragment, not full-length growth hormone.
The larger oral obesity program failed to show the required weight-loss benefit.
A published safety summary is not a new positive efficacy trial.
Later LAT8881 studies concern different outcomes and formulations; they do not validate retail research vials.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This commercially interested, AI-assisted summary is not an independent scientific review. Selected sources were checked November 11, 2026; access limits appear below.

1. What do AOD-9604 and LAT8881 identify?
AOD-9604 is a 16-amino-acid peptide modeled on the C-terminal region of human growth hormone. FDA distinguishes its free base and acetate form. A relationship to growth hormone is a chemical starting point, not evidence that the fragment shares all of the hormone's effects. FDA AOD-9604 assessment — PDF
FDA's substance registry places AOD9604, AOD-9604, LAT8881 and LAT-8881 under the same identity record, UNII 7UP768IP4M. The registry explicitly says that having a UNII does not imply approval. These aliases matter when searching for studies. Official substance record
Shared molecular identity does not make every capsule, clinical preparation and laboratory vial interchangeable. Formulation, route, manufacturing controls and the condition being studied remain separate questions.
2. What happened in the obesity trials?
The development program progressed from smaller studies to the OPTIONS trial. In February 2007, the sponsor announced that weight-loss differences from placebo were not statistically significant at either 12 or 24 weeks and ended development for obesity. This was a sponsor announcement, not a detailed peer-reviewed efficacy paper. Original exchange announcement — PDF
Record | What was studied or reported | What it can establish |
|---|---|---|
Registered oral obesity study, also identified as METAOD006 | The planned outcomes and design; registration alone is not a positive result. | |
Larger placebo-controlled obesity study with diet and exercise support | Reported failure to separate from placebo for weight loss; detailed independent analysis is limited by the report's format. | |
Summary of six earlier trials using oral or intravenous preparations | Safety observations from the development program, not six new demonstrations of weight-loss efficacy. | |
Later oral crossover trial in people with diabetic peripheral neuropathy or post-herpetic neuralgia | Posted pain results did not establish superiority; it did not test weight loss. |
The participant counts require care. FDA reports 536 enrolled and 502 randomized for OPTIONS; the 2013 paper reports 534 enrolled and the same 502 randomized. The checked sources do not resolve that enrollment discrepancy. These are not interchangeable counts of people who completed treatment. FDA trial summary — PDF
A trial can produce weight loss in both groups without demonstrating an additional effect of the active intervention. The relevant comparison is the difference attributable to treatment under the trial conditions. Diet-and-exercise support does not make a negative placebo comparison disappear.
3. What does the safety publication actually support?
The 2013 report summarized six studies involving 893 participants, with differing routes and durations. It reported no significant increase in circulating IGF-1 and no detected anti-AOD9604 antibodies in the tested samples. Those observations address particular laboratory questions; they do not establish efficacy or eliminate every possible harm. Original safety report
Its reassuring overall language also needs to be read against the study-level details. One oral study describes diarrhea as a serious adverse event considered possibly related to treatment, despite broader claims elsewhere in the paper about no related serious events. The report discloses sponsor funding and commercial interests. An evidence summary should retain that inconsistency rather than repeat the most reassuring sentence in isolation. Safety report, individual-study results and disclosures
Safety is conditional on what was tested. An absence of a particular antibody response during a defined study does not settle risks from another formulation, impurity profile or longer exposure. Likewise, a hormone marker that remains unchanged is not a substitute for demonstrating meaningful fat loss or improved health.
4. Why do the later LAT8881 records matter?
The oral neuropathic-pain study enrolled 53 participants. Its primary per-protocol analysis included 50 and estimated a net pain-score difference of −0.14 points, with a 95% confidence interval of −0.76 to 0.49 and P=0.67. This did not establish a benefit over placebo. The crossover design means the treatment-period denominators must not be added together as if they were separate people. Posted trial results
Other posted LAT8881 records include an acute-migraine study and an intravenous study with a lumbar-radicular-pain component. Their existence prevents a blanket “no human injectable research” claim. It does not establish a successful weight-loss treatment by another route. Migraine record, intravenous research record
This is a useful distinction between identity and evidence: aliases help locate records, but a result in one condition cannot answer a different clinical question. Our study-reading guide explains how to keep intervention, population and outcome connected.
5. What remains unresolved about approval and future work?
FDA's 2024 review stated that the evaluated AOD-9604 forms were not components of an FDA-approved drug. Current name-based approval-database checks did not identify a matching product. FDA's safety page flags possible immune reactions, impurity concerns and serious-event reports with uncertain causality. FDA assessment — PDF, current safety information
Neither a substance identifier nor a research-use-only label confers approval for personal treatment. A published study also does not certify the contents of a supplied lot. The COA checklist addresses analytical documentation, which answers a different question from clinical effectiveness.
Future work would need to define the proposed indication and formulation, report full prespecified outcomes, explain missing data and provide adequate safety follow-up. Any renewed obesity claim would need new controlled evidence that addresses the earlier failure. It cannot be established by relabeling a negative trial as a safety success or by borrowing findings from another growth-hormone-related material. The tesamorelin evidence guide illustrates why another peptide's distinct clinical program must remain separate.
Review method and source access: Selected FDA sections, the full 2013 safety report, the sponsor's original results announcement, official identity records and registry entries/results were examined. Individual participant data and the full original obesity clinical-study reports were not accessed. This is a selected review, not an exhaustive trial inventory or an independent clinical assessment.
